Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

By sjmartinez • October 26, 2023

Neelapu SS, Chavez JC, Sehgal A, Epperla N, Ulrickson ML, Bachy E, Munshi P, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO Dr, Yakoubagha I, Khanal R, Rosenblatt JD, Korn R, Peng W, Lui C, Wullf J, Shen RR, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA. Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5). Blood. 2023 Oct 25:blood.2023021243. doi: 10.1182/blood.2023021243. Epub ahead of print. PMID: 37879047.

Tags: Hematology/Oncology, Publications

Navigating Complexity: A Case Study on Hemophagocytic Lymphohistiocytosis Diagnosis and Management Challenges

Nguyen J, Tun N, Burley N, Bolos D. Navigating Complexity: A Case Study on Hemophagocytic Lymphohistiocytosis Diagnosis and Management Challenges. Cureus. 2024 May 4;16(5):e59628. doi:[...]

Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma

Cai J, Varda M, Sin D, Overby H, Yeh JJ. Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma. Clin Case Rep. 2024 May[...]

Generalizability of PGS313 for breast cancer risk in a Los Angeles biobank

Shang H, Ding Y, Venkateswaran V, Boulier K, Kathuria-Prakash N, Malidarreh PB, Luber JM, Pasaniuc B. Generalizability of PGS313 for breast cancer risk in a Los[...]